ATC Group: G02AD Prostaglandins

The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.

Position of G02AD in the ATC hierarchy

Level Code Title
1 G Genito urinary system and sex hormones
2 G02 Other gynecologicals
3 G02A Oxytocics
4 G02AD Prostaglandins

Group G02AD contents

Code Title
G02AD01 Dinoprost
G02AD02 Dinoprostone
G02AD03 Gemeprost
G02AD04 Carboprost
G02AD05 Sulprostone
G02AD06 Misoprostol

Active ingredients in G02AD

Active Ingredient

Carboprost is a synthetic 15-methyl analogue of dinoprost (prostaglandin F2 alpha). Administered intramuscularly carboprost stimulates in the gravid uterus myometrial contractions similar to labor contractions at the end of a full term pregnancy. It is indicated for aborting pregnancy between the 13th and 20th weeks of gestation as calculated from the first day of the last normal menstrual period and for the treatment of postpartum hemorrhage due to uterine atony, which has not responded to conventional methods of management. The most frequent adverse reactions observed are related to its contractile effect on smooth muscle: vomiting, diarrhea, nausea, fever and flushing. Carboprost may augment the activity of other oxytocic agents. Concomitant use with other oxytocic agents is not recommended.

Gemeprost (16, 16-dimethyl-trans-delta2 PGE1 methyl ester) is a prostaglandin E1 analogue. Both in pregnant and non-pregnant animals, it causes contraction of the uterus and causes softening and decreases resistance of cervical tissue. Gemeprost depresses placental and uterine blood flow but those actions are secondary to the main uterine stimulation.

Misoprostol is an analogue of naturally occurring prostaglandin E1 which promotes peptic ulcer healing and symptomatic relief. Misoprostol protects the gastroduodenal mucosa by inhibiting basal, stimulated and nocturnal acid secretion and by reducing the volume of gastric secretions, the proteolytic activity of the gastric fluid, and increasing bicarbonate and mucus secretion.

Related product monographs

Document Type Information Source  
 ANGUSTA Tablet MPI, EU: SmPC Medicines & Healthcare Products Regulatory Agency (GB)
 CERVAGEM Vaginal pessary MPI, EU: SmPC Medicines & Healthcare Products Regulatory Agency (GB)
 CERVIDIL Vaginal insert MPI, US: SPL/PLR FDA, National Drug Code (US)
 HEMABATE Solution for injection MPI, EU: SmPC Medicines & Healthcare Products Regulatory Agency (GB)
 PRANDIN E2 Vaginal Gel MPI, Generic Marketing Authorisation Holder
 PREPIDIL Gel MPI, US: SPL/Old FDA, National Drug Code (US)
 PROSTIN E2 Concentrate for solution for infusion MPI, EU: SmPC Medicines & Healthcare Products Regulatory Agency (GB)
 PROSTIN E2 Vaginal tablet MPI, EU: SmPC Medicines & Healthcare Products Regulatory Agency (GB)
 TOPOGYNE Tablet MPI, EU: SmPC Medicines & Healthcare Products Regulatory Agency (GB)